Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm.
In a study comparing fotemustine and DTIC, patients receiving fotemustine had a median survival of 7.3 months compared to 5.6 months for those receiving DTIC (P=.067). Additionally, toxicity was observed more frequently in the fotemustine group.